logo
Acute Kidney Injury: From Early Signs to Chronic Risk

Acute Kidney Injury: From Early Signs to Chronic Risk

Acute kidney injury (AKI) isn't just a short-term problem—it's the start of a longer kidney health journey. AKI was previously called 'acute renal failure' or 'renal failure' but the terminology has evolved to reflect the spectrum of kidney injury. AKI occurs when the kidneys suddenly stop filtering waste products from the blood and the kidney function changes rapidly. This complication is very different from diseases such as Polycystic Kidney Disease, which is a genetic disease and genetic disorder caused by gene mutations passed from biological parents to their children.
Whether it happens in the ICU or outpatient clinic AKI carries a big burden: increased risk of hospitalization, long term dialysis and even premature death. AKI is common in hospitalized patients and patients admitted to hospital and impacts outcomes and length of stay.
Recognizing it early, treating it promptly and understanding the link to chronic kidney disease (CKD) is key to preserving kidney function and better patient outcomes. AKI and CKD are both forms of renal disease and show the continuum between acute and chronic conditions.
Let's look at how AKI is classified, how to detect it early and what modern tools and strategies are helping clinicians change the trajectory from injury to recovery.
AKI is classified by where the problem starts:
The KDIGO clinical practice guideline (Kidney Disease: Improving Global Outcomes) defines AKI using changes in serum creatinine levels and urine output. The urine output criteria are also used in AKI staging, such as less than 0.5 mL/kg/h for specified durations.
The Acute Kidney Injury Network (AKIN) is another classification system that incorporates both serum creatinine and urine output criteria. Early detection and classification are key, with identification of renal dysfunction and monitoring of glomerular filtration rate (GFR) as key measures of kidney health.
But while these have been the clinical mainstays, they aren't always fast or specific enough to catch injury early. Serum creatinine level and blood urea nitrogen are traditional markers for assessing renal function but both have limitations in sensitivity and specificity.
That's where newer biomarkers like neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1) and cystatin C come in. These tools are changing early detection, helping clinicians distinguish between mild, reversible cases and more severe or ongoing damage [2] [3].
A 2021 article highlights the importance of fluid balance, electrolyte monitoring and timely renal replacement therapy (RRT) when AKI is confirmed [3]. In the outpatient space, some reviews suggest early medication adjustment and specialist referrals can reduce complications in patients managed outside the hospital [4].
In the context of pathophysiology blood clots can cause vascular obstruction leading to AKI and red blood cells may be seen in kidney biopsies in certain conditions such as anticoagulant-related nephropathy. [5]
Prevention starts by identifying who's most at risk. People with diabetes, hypertension, chronic heart failure, or advanced age are more likely to develop AKI—especially during acute illnesses or when exposed to nephrotoxic medications like NSAIDs or contrast agents. Both patient-related and treatment-related risk factors such as underlying chronic diseases, recent infections, trauma or major surgeries play a key role in increasing the likelihood of AKI.
According to a 2020 Journal of Clinical Medicine review, risk mitigation means taking a proactive, team-based approach: monitor hydration, avoid nephrotoxins and assess kidney function during high-risk scenarios like surgery or infection [7]. It's especially important to identify high risk patients, such as those undergoing major procedures like cardiac surgery and tailor perioperative management strategies to prevent renal complications.
Hospital-based strategies such as standardized monitoring protocols and early nephrology involvement can also reduce AKI rates as emphasized by the American Journal of Kidney Diseases Core Curriculum [11].
In a more recent 2025 article in Lakartidningen Swedish clinicians advocate for a streamlined system to identify and intervene early in AKI cases, especially in older adults or those with fluctuating blood pressure [10].
Relying solely on serum creatinine to assess kidney health is a bit like using a smoke detector after the fire's already burning. Biomarkers offer a more sensitive way to detect kidney injury before significant function is lost. Blood tests are essential for detecting changes in kidney function and guiding the management of AKI patients.
A 2022 review in Medicina presents compelling evidence that biomarkers can guide both diagnosis and risk stratification, helping clinicians decide when to intensify care or when to hold off on aggressive treatments [6].
These biomarkers also help distinguish between transient AKI (due to things like dehydration) and persistent AKI, which is more likely to result in long-term damage. This distinction is critical when managing critically ill patients or adjusting medications like ACE inhibitors and diuretics.
One of the biggest changes in kidney medicine over the past decade is that AKI doesn't always resolve cleanly. Many patients recover creatinine levels but their kidneys never return to full health. This transitional phase, called acute kidney disease (AKD), spans from 7 to 90 days after AKI onset. Renal recovery after AKI depends on factors such as the severity of injury, underlying comorbidities and the presence of biomarkers indicating renal repair mechanisms.
A 2022 Nephron review calls AKD the 'missing link' between AKI and CKD, emphasizing the need for follow-up labs and patient education [8]. If kidney function hasn't bounced back within that 90-day window CKD is usually diagnosed.
New research in the Yonsei Medical Journal shows how early post-discharge care—such as nephrology visits, medication reviews and blood pressure control—can slow progression to irreversible kidney damage [9]. Kidney disease progression after AKI increases the risk of developing chronic renal failure, chronic kidney failure, end stage kidney disease and end stage renal disease.
Meanwhile a 2024 American Journal of Physiology review looks into the biological mechanisms behind this progression. It points to inflammation, fibrosis (scarring) and microvascular injury as key drivers—and possible therapeutic targets—of the AKI-to-CKD transition [12]. Cardiovascular disease is also a major cause of morbidity and mortality in patients with a history of AKI.
When it comes to managing AKI a few core principles apply across both hospital and outpatient settings:
The Acute Dialysis Quality Initiative (ADQI) has developed consensus guidelines and classification systems for AKI management.
The sooner these are implemented the better the chances of preventing permanent kidney damage and the slide to CKD.
Acute kidney injury is more than a short term health crisis—it's a long term disease. As we learn more about AKI we have more opportunity to intervene early, personalize care and protect long term kidney health. By using advanced biomarkers, prevention focused strategies and recognizing AKD as a key phase clinicians can change the story for thousands of patients with kidney injury every year.
[1] Rahman, M., Shad, F., & Smith, M. C. (2012). Acute kidney injury: a guide to diagnosis and management. American family physician, 86(7), 631–639. https://pubmed.ncbi.nlm.nih.gov/23062091/
[2] Mercado, M. G., Smith, D. K., & Guard, E. L. (2019). Acute Kidney Injury: Diagnosis and Management. American family physician, 100(11), 687–694. https://pubmed.ncbi.nlm.nih.gov/31790176/
[3] Kellum, J. A., Romagnani, P., Ashuntantang, G., Ronco, C., Zarbock, A., & Anders, H. J. (2021). Acute kidney injury. Nature reviews. Disease primers, 7(1), 52. https://doi.org/10.1038/s41572-021-00284-z
[4] Jacob, J., Dannenhoffer, J., & Rutter, A. (2020). Acute Kidney Injury. Primary care, 47(4), 571–584. https://doi.org/10.1016/j.pop.2020.08.008
[5] Neyra, J. A., & Chawla, L. S. (2021). Acute Kidney Disease to Chronic Kidney Disease. Critical care clinics, 37(2), 453–474. https://doi.org/10.1016/j.ccc.2020.11.013
[6] Yoon, S. Y., Kim, J. S., Jeong, K. H., & Kim, S. K. (2022). Acute Kidney Injury: Biomarker-Guided Diagnosis and Management. Medicina (Kaunas, Lithuania), 58(3), 340. https://doi.org/10.3390/medicina58030340
[7] Gameiro, J., Fonseca, J. A., Outerelo, C., & Lopes, J. A. (2020). Acute Kidney Injury: From Diagnosis to Prevention and Treatment Strategies. Journal of clinical medicine, 9(6), 1704. https://doi.org/10.3390/jcm9061704
[8] Levey A. S. (2022). Defining AKD: The Spectrum of AKI, AKD, and CKD. Nephron, 146(3), 302–305. https://doi.org/10.1159/000516647
[9] Koh, E. S., & Chung, S. (2024). Recent Update on Acute Kidney Injury-to-Chronic Kidney Disease Transition. Yonsei medical journal, 65(5), 247–256. https://doi.org/10.3349/ymj.2023.0306
[10] Bell, M., M Öberg, C., & Ewert Broman, M. (2025). Akut njurskada – prevention och behandling [Acute kidney injury - prevention and treatment]. Lakartidningen, 122, 23182. https://pubmed.ncbi.nlm.nih.gov/40421748/
[11] Moore, P. K., Hsu, R. K., & Liu, K. D. (2018). Management of Acute Kidney Injury: Core Curriculum 2018. American journal of kidney diseases : the official journal of the National Kidney Foundation, 72(1), 136–148. https://doi.org/10.1053/j.ajkd.2017.11.021
[12] Zhang, T., Widdop, R. E., & Ricardo, S. D. (2024). Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers. American journal of physiology. Renal physiology, 327(5), F788–F805. https://doi.org/10.1152/ajprenal.00184.2024
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cystatin C May Predict Outcomes in AKI and Liver Cirrhosis
Cystatin C May Predict Outcomes in AKI and Liver Cirrhosis

Medscape

time3 days ago

  • Medscape

Cystatin C May Predict Outcomes in AKI and Liver Cirrhosis

TOPLINE: In patients hospitalized with acute kidney injury (AKI) and liver cirrhosis, higher levels of peak serum cystatin C were associated with an increased risk for inhospital mortality, whereas lower baseline levels of the biomarker predicted better odds of renal recovery. METHODOLOGY: Cystatin C, a 13-kDa nonglycosylated protein produced by all nucleated cells, has been reported as an early predictor of AKI development in patients with liver cirrhosis; however, little is known about its role in predicting AKI recovery in this population. Researchers conducted a retrospective cohort study to investigate whether serum levels of cystatin C could predict kidney function recovery and mortality in adults with liver cirrhosis and AKI (N = 209; 97 women; mean age, 56 years) hospitalized between May 2017 and May 2023. Serum creatinine and cystatin C were measured within 7 days of admission, with the peak cystatin C level corresponding to the values taken on the same day as peak creatinine level; medical history and data on admission laboratory parameters were also retrieved. Outcomes included inhospital mortality, renal recovery, length of hospital stay, and the need for renal replacement therapy. Complete renal recovery was defined as serum creatinine levels returning to within 50% above baseline, and partial renal recovery was defined as discharge without the need for renal replacement therapy but not meeting the complete recovery criteria. TAKEAWAY: Overall, 31% of patients died during hospital admission, 34.9% achieved complete renal recovery, and 30.1% achieved partial renal recovery. Higher peak level of serum cystatin C emerged as a significant predictor of inhospital mortality (odds ratio [OR], 2.808; P ≤ .001); other predictors were serum albumin level (OR, 0.364; P = .013) and white blood cell count (OR, 1.085; P = .021). Lower baseline serum levels of cystatin C predicted renal recovery (OR, 0.446; P ≤ .001); other predictors were hypertension, along with higher serum albumin, and baseline serum creatinine levels (P < .05 for all). A peak serum cystatin C threshold of 2.77 mg/L predicted inhospital mortality with 79% sensitivity and 62% specificity, whereas a baseline threshold of 2.62 mg/L predicted renal recovery with 65% sensitivity and 64% specificity. IN PRACTICE: 'Integrating serum cystatin C assessment into the management of AKI patients can help identify those with elevated levels who may benefit from targeted medical interventions to improve their outcomes,' the authors of the study wrote. SOURCE: This study was led by Eman Nagy, Mansoura University, Mansoura, Egypt. It was published online in BMC Nephrology. LIMITATIONS: This study was retrospective and conducted at a single center. Improvement of kidney function was defined only by serum creatinine levels without considering urine output. The causes of AKI or underlying etiology of liver cirrhosis were unknown. DISCLOSURES: This study did not receive any specific funding. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Business Wire

time6 days ago

  • Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences, Inc. (NASDAQ: REVB) (the 'Company' or 'Revelation'), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights "The Revelation team continues to strategically maximize its financial resources to achieve our stated objectives and advance the Gemini program," said James Rolke, Chief Executive Officer of Revelation. "We look forward to announcing data from the Phase 1b study later this quarter and engaging with the FDA later this year to further the clinical development of Gemini and enhance shareholder value." Results of Operations As of June 30, 2025, Revelation had $5.2 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024. The decrease in cash and cash equivalents was primarily due to cash used for operating activities. Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations through December 2025. Revelation's net cash used for operating activities for the three months ended June 30, 2025 was $4.7 million compared to net cash used for operating activities of $5.3 million for the same period in 2024. Revelation's net loss for the three months ended June 30, 2025 was $2.4 million, or $(7.01) basic and diluted net loss per share compared to a net loss of $8.4 million, or $(246.27) basic and diluted net loss per share for the same period in 2024. Revelation's net loss for six months ended June 30, 2025 was $4.5 million, or $(13.60) basic and diluted net loss per share compared to net loss of $11.1 million, or $(390.02) basic and diluted net loss per share for the same period in 2024. About Gemini Gemini is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD ®) that reduces the damage associated with inflammation by reprogramming the innate immune system to respond to stress (trauma, infection, etc.) in an attenuated manner. Gemini is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program), and as pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program), or infection post severe burn (GEMINI-PBI). Gemini may also be a treatment to stop or slow the progression of chronic kidney disease (GEMINI-CKD program). Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications. Revelation previously announced positive Phase 1 clinical data for intravenous treatment with Gemini: the primary safety endpoint was met in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity, as observed through expected changes in multiple biomarkers including upregulation of IL-10. About Revelation Biosciences, Inc. Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease. For more information on Revelation, please visit Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation. REVELATION BIOSCIENCES, INC. Consolidated Balance Sheets June 30, December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 5,173,871 $ 6,499,018 Prepaid expenses and other current assets 186,049 66,699 Total current assets 5,359,920 6,565,717 Property and equipment, net 35,170 56,332 Total assets $ 5,395,090 $ 6,622,049 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 828,894 $ 783,621 Accrued expenses 739,626 1,127,800 Warrant liability 786 2,246 Total current liabilities 1,569,306 1,913,667 Total liabilities 1,569,306 1,913,667 Commitments and Contingencies (Note 4) Stockholders' equity: Common Stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2025 and December 31, 2024 and 1,534,637 and 174,104 issued and outstanding at June 30, 2025 and December 31, 2024, respectively 1,535 174 Additional paid-in-capital 48,825,354 45,213,846 Accumulated deficit (45,001,105 ) (40,505,638 ) Total stockholders' equity 3,825,784 4,708,382 Total liabilities and stockholders' equity $ 5,395,090 $ 6,622,049 Expand

Severe AKI Tied to Reduced Survival in Patients on ECMO
Severe AKI Tied to Reduced Survival in Patients on ECMO

Medscape

time7 days ago

  • Medscape

Severe AKI Tied to Reduced Survival in Patients on ECMO

TOPLINE: A notable proportion of patients receiving veno-venous extracorporeal membrane oxygenation (ECMO) for acute respiratory failure developed acute kidney injury (AKI), likely due to the greater severity of the underlying disease. Severe AKI was independently associated with reduced hospital survival, regardless of whether it occurred before or during ECMO. METHODOLOGY: Researchers conducted a retrospective cohort study to evaluate the prevalence, survival, and risk factors for AKI in 500 patients undergoing veno-venous ECMO for acute respiratory failure (median age, 55 years; 30% women). Patients were categorised into three groups: those with the onset of AKI before ECMO, those with its onset during ECMO, and those with its onset both before ECMO and a new onset of AKI during ECMO after an initial recovery. AKI was defined according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Patients were followed up for survival up to 1 year after hospital discharge to assess long-term outcomes. Propensity score matching was performed between patients without AKI and those with its onset during ECMO to analyse risk factors. TAKEAWAY: Overall, 64% (n = 320) developed AKI, 182 of whom had the onset of the condition before ECMO and 158 during ECMO. The overall survival to hospital discharge was 67% (n = 335), with severe AKI (KDIGO stage 3) associated with reduced hospital survival regardless of its onset before or during ECMO (P = .001). Patients with the onset of AKI before veno-venous ECMO had significantly higher levels of inflammatory markers and required higher doses of norepinephrine at the initiation of ECMO than those without AKI, highlighting a greater severity of the underlying disease. Similarly, among patients who developed vs did not develop AKI during ECMO, markers of disease severity and sepsis such as high organ failure scores, high levels of C reactive protein, and low mean arterial pressure emerged as risk factors. IN PRACTICE: "AKI is a frequent complication in patients supported with VV [veno-venous]-ECMO. AKI onset before VV-ECMO-therapy is linked to the severity of the underlying disease. AKI onset during VV-ECMO is less due to ECMO-related factors but also to the severity of the disease and septic episodes," the authors wrote. SOURCE: This study was led by Franziska Fuchs and Clemens Wiest, University Hospital Regensburg in Regensburg, Germany. It was published online on August 01, 2025, in Kidney360. LIMITATIONS: The study's retrospective design limited its generalisability and the establishment of causal conclusions. Data on patients before hospital admission were limited. The prevalence of AKI may have been affected by using creatinine alone for diagnosis and the lack of baseline data on creatinine and urine output. DISCLOSURES: No funding information was provided for this study. Some authors declared being employees, board or committee members, advisors, or consultants of various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store